Indeed, we have observed that RelB-positive patient samples were also positive for RelA, and knockdown of RelA expression in MM cell lines leads to a marked increase in apoptosis, thus supporting the idea that an efficient anti-NF-κB therapeutic approach should target both RelA and RelB activation in MM. This evidence concerns the gene NFKB1 and Miyoshi myopathy.